Cargando…

Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations

Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sejben, Anita, Pancsa, Tamás, Tiszlavicz, László, Furák, József, Paróczai, Dóra, Zombori, Tamás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067356/
https://www.ncbi.nlm.nih.gov/pubmed/36808895
http://dx.doi.org/10.1111/1759-7714.14827
_version_ 1785018446777417728
author Sejben, Anita
Pancsa, Tamás
Tiszlavicz, László
Furák, József
Paróczai, Dóra
Zombori, Tamás
author_facet Sejben, Anita
Pancsa, Tamás
Tiszlavicz, László
Furák, József
Paróczai, Dóra
Zombori, Tamás
author_sort Sejben, Anita
collection PubMed
description Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic, and sarcomatoid MM. Distinction may be a challenging task for the pathologist, due to the unspecific morphology. Here, we present two cases of diffuse MM subtypes to emphasize the immunohistochemical (IHC) differences, and to facilitate diagnostic difficulties. In our first case of epithelioid mesothelioma, the neoplastic cells showed cytokeratin 5/6 (CK5/6), calretinin, and Wilms‐tumor‐1 (WT1) expression, while remaining negative with thyroid transcription factor‐1 (TTF‐1). BRCA1 associated protein‐1 (BAP1) negativity was seen in the neoplastic cells' nucleus, reflecting loss of the tumor suppressor gene. In the second case of biphasic mesothelioma, expression of epithelial membrane antigen (EMA), CKAE1/AE3, and mesothelin was observed, while WT1, BerEP4, CD141, TTF1, p63, CD31, calretinin, and BAP1 expressions were not detected. Due to the absence of specific histological features, the differentiation between MM subtypes could be a challenging task. In routine diagnostic work, IHC may be the proper method in distinction. According to our results and literature data, CK5/6, mesothelin, calretinin, and Ki‐67 should be applied in subclassification.
format Online
Article
Text
id pubmed-10067356
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-100673562023-04-04 Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations Sejben, Anita Pancsa, Tamás Tiszlavicz, László Furák, József Paróczai, Dóra Zombori, Tamás Thorac Cancer Mini Review Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic, and sarcomatoid MM. Distinction may be a challenging task for the pathologist, due to the unspecific morphology. Here, we present two cases of diffuse MM subtypes to emphasize the immunohistochemical (IHC) differences, and to facilitate diagnostic difficulties. In our first case of epithelioid mesothelioma, the neoplastic cells showed cytokeratin 5/6 (CK5/6), calretinin, and Wilms‐tumor‐1 (WT1) expression, while remaining negative with thyroid transcription factor‐1 (TTF‐1). BRCA1 associated protein‐1 (BAP1) negativity was seen in the neoplastic cells' nucleus, reflecting loss of the tumor suppressor gene. In the second case of biphasic mesothelioma, expression of epithelial membrane antigen (EMA), CKAE1/AE3, and mesothelin was observed, while WT1, BerEP4, CD141, TTF1, p63, CD31, calretinin, and BAP1 expressions were not detected. Due to the absence of specific histological features, the differentiation between MM subtypes could be a challenging task. In routine diagnostic work, IHC may be the proper method in distinction. According to our results and literature data, CK5/6, mesothelin, calretinin, and Ki‐67 should be applied in subclassification. John Wiley & Sons Australia, Ltd 2023-02-20 /pmc/articles/PMC10067356/ /pubmed/36808895 http://dx.doi.org/10.1111/1759-7714.14827 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mini Review
Sejben, Anita
Pancsa, Tamás
Tiszlavicz, László
Furák, József
Paróczai, Dóra
Zombori, Tamás
Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
title Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
title_full Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
title_fullStr Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
title_full_unstemmed Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
title_short Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
title_sort highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067356/
https://www.ncbi.nlm.nih.gov/pubmed/36808895
http://dx.doi.org/10.1111/1759-7714.14827
work_keys_str_mv AT sejbenanita highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations
AT pancsatamas highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations
AT tiszlaviczlaszlo highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations
AT furakjozsef highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations
AT paroczaidora highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations
AT zomboritamas highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations